# Viome Life Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/viome-life-sciences

- Industry: Biotechnology
- Headquarters: Bellevue, US
- Website: www.viome.com
- Total disclosed funding: $234M
- Latest round: Series D (Aug 19, 2024)
- Investors on record: 8

## About

Viome, Inc. is a U.S.-based biotech firm specializing in at-home microbiome health assessments, offering personalized health insights through advanced RNA sequencing technology to improve overall well-being.Founded in 2016 and headquartered in Bellevue, US, Viome Life Sciences, Inc. focuses on delivering microbiome health testing solutions. The company has executed 10 significant deals, with the most recent funding round being Series D, in which it raised USD 25.443 mn from lead investors including Bold Capital Partners, Khosla Ventures, and West River Group. The total amount raised amounts to USD 25.443 mn, currently valuing the company at USD 366.201 mn.Viome Life Sciences specializes in at-home microbiome health testing, primarily offering three core products: the Full Body Intelligence™ Test, the Gut Intelligence™ Test, and the Oral Health Intelligence™ Test. These tests utilize RNA sequencing technology to analyze the activities of the microbiome and cellular functions, providing users with personalized health insights and recommendations tailored to their unique biological profiles. The end use cases for these products include addressing digestive issues, optimizing energy levels, improving mood and cognitive function, and enhancing overall health and wellness. Viome primarily serves individual consumers seeking personalized health solutions and has a growing customer base that includes health-conscious individuals, athletes, health coaches, and those suffering from chronic health issues. The company markets its products across several geographical regions, including the United States, Canada, and select international markets.Viome operates on a direct-to-consumer model, generating revenue through the sale of its microbiome health tests and personalized product subscriptions. Customers can purchase individual tests or opt for health solution bundles that include monthly deliveries of custom-formulated supplements and biotic formulas designed based on test results. The pricing structure typically involves one-time payments for individual tests, while subscription services for personalized products create a recurring revenue stream. Viome's flagship offerings, such as the Full Body Intelligence™ Test, are part of these transactions, enabling customers to receive actionable insights into their health. The company emphasizes the value of data-driven personalization in its revenue strategy, fostering long-term engagement with clients through tailored health solutions.In August 2024, Viome, Inc. raised USD 25.4 mn in Series D funding, which will be utilized to launch its diagnostic division and enhance its offerings. The company is planning to expand its product lineup and enter new geographic markets to further its reach. Specific expansion plans include targeting additional international markets by the end of 2025.

## Funding rounds

- Series D, Aug 19, 2024, $25M — Khosla Ventures, West River Group, BOLD Capital Partners
- Series C, Aug 18, 2023, $87M — Khosla Ventures, West River Group, BOLD Capital Partners
- Series C, Sep 27, 2022, $67M — Khosla Ventures, Ezaki Glico, West River Group, BOLD Capital Partners, Physician Partners, LLC
- Series B, Apr 17, 2019, $25M — Khosla Ventures, Nomad Capital, Hambrecht Capital, BOLD Capital Partners, Physician Partners, LLC
- Series B, Aug 2, 2018, $9.1M — CerraCap Ventures
- Series B, Jun 21, 2018, $5.5M — Khosla Ventures, Physician Partners, LLC
- Series A, Jul 28, 2017, $15M — Khosla Ventures, BOLD Capital Partners

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series A, Series B, Series C, Series D
- BOLD Capital Partners (https://capitalatlas.ai/funds/bold-capital-partners) — Series A, Series B, Series C, Series D
- Physician Partners, LLC — Series B, Series C
- CerraCap Ventures (https://capitalatlas.ai/funds/cerracap-ventures) — Series B
- Nomad Capital — Series B
- Hambrecht Capital (https://capitalatlas.ai/funds/hambrecht-capital) — Series B
- Ezaki Glico — Series C
- West River Group — Series C, Series D